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preproGRP transcripts were found in 28% of the blood samples.
The detection of a hematogenic tumor cell spread with preproGRP
in MTC correlated significantly with advanced tumor categories.
CK20 transcripts were detected in 75% of the blood samples of
patients with thyroid carcinoma and distant metastases. More-
over disseminated tumor cells were detected in 21% of the bone
marrow samples with CK20-PCR and 13% with preproGRP (only
for MTC).
Conclusion: Both assays are sensitive enough to detect dissemi-
nated thyroid carcinoma cells in blood and bone marrow sam-
ples. However, the prognostic relevance of these disseminated
tumor cells is not completely understood and has to be addressed
in further investigations.
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S52. Pdcd4 TARGETS eIF4A TO INHIBIT TRANSLATION,
TRANSCRIPTION, TUMORIGENESIS, AND INVASION
Nancy H. Colburn, Hsin-Sheng Yang, Aaron Jansen. Laboratory of
Cancer Prevention, National Cancer Institute, Frederick, MD 21702,
USA.
Despite its name, Programmed Cell Death 4 (Pdcd4) may or may
not induce apoptosis. Pdcd4 was discovered as a highly expressed
gene in mouse JB6 cells resistant to transformation. Pdcd4 inhib-
its transformation and tumorigenesis, in part by specifically
inhibiting AP-1 dependent transcription. The binding partners
of Pdcd4 are not Jun or Fos proteins but are translation initiation
factors eIF4A and eIF4G. Pdcd4 inhibits translation initiation by
directly binding to translation initiation factor eIF4A and inhibit-
ing its helicase activity. The helicase activity of eIF4A is important
for unwinding 5 0UTR structured mRNAs prior to scanning to the
translational start site. Pdcd4 also interferes with scaffold eIF4G
function. Pdcd4 must interact with eIF4A and inhibit translation
in order to inhibit AP-1 transactivation, as Pdcd4 mutants inacti-
vated for eIF4A binding fail to inhibit AP-1. Recent findings with
K14-driven Pdcd4 expression in mice have established that Pdcd4
inhibits translation of a 5 0UTR-structured mRNA as well as
expression of ‘‘translationally repressed’’ proteins. Pdcd4 inhibits
AP-1 dependent transcription and acts to attenuate papilloma-
genesis and papilloma to carcinoma conversion. Moreover Pdcd4
expression (a) is downregulated with progression in several
human cancer sites, (b) confers sensitivity to certain therapeutic
drugs, and (c) suppresses invasion and motility in human cancer
cell lines. Pdcd4 suppresses cancer cell invasion by targeting the
expression of MAP4K1, an upstream regulator of Jun N-terminal
Kinase signaling, with consequent inhibition of AP-1 dependent
transcription. Thus, activating or mimicking the expression of
Pdcd4 might be an attractive preventive or therapeutic strategy.
Enhancing the interaction of Pdcd4 with eIF4A or targeting down-
stream translational targets may produce the ‘‘desired’’ but not
the ‘‘undesired’’ outcomes achieved with mTOR inhibitors. mTOR
inhibitors repress translation by enhancing the interaction of 4E-
BP with cap binding protein eIF4E but are also immunosuppres-
sive. Pdcd4 appears not to show immunosuppressive activity.
Although we and others have identified translationally repressed
candidates, the functionally significant translational targets of
Pdcd4 are still unknown. Knowing these Pdcd4 targets is impor-
tant for designing prevention strategies. In summary, Pdcd4 is
the first suppressor of tumorigenesis and invasion known to
directly inhibit translation initiation. Translation initiation thus
appears to be a promising molecular target for cancer prevention
and intervention.
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S53. THE ISEL AND BR21 TRIALS – OUTCOMES SIMILAR OR
DIFFERENT?
Nick Thatcher. Christie Hospital, Manchester, UK.
The survival effects of EGFR-TKI therapy have been evaluated in
two Phase III placebo-controlled studies in refractory NSCLC: ISEL
(IRESSA Survival Evaluation in Lung cancer no. = 1692) and BR21
(erlotinib no. = 731).1,2 Gefitinib (Iressa) showed some improve-
ment in survival compared with placebo, but the difference did
not reach statistical significance on the prespecified stratified
log rank test required for registration in either the overall popula-
tion (HR 0.89; p = 0.087; median 5.6 vs. 5.1 months) or in patients
with adenocarcinoma (HR 0.84; p = 0.089; median 6.3 vs. 5.4
months). However, preplanned subgroup analyses showed that
gefitinib significantly prolonged survival in patients of Asian eth-
nicity and in patients who had never smoked. The erlotinib BR21
study had a similar design to ISEL, but demonstrated a statisti-
cally significant overall survival benefit for erlotinib HR = 0.7
p < 0.001 median 6.7 vs. 4.7 months.2 However the 95% confidence
intervals for the HRs overlap ISEL 0.77–1.02 and 0.58–0.85 for BR21
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suggesting a similar overall survival benefit for the two drugs.
Furthermore survival subset analyses in BR21 were consistent
with ISEL, with the largest survival benefits for erlotinib also seen
in the never-smoking and Asian subgroups. The objective
response rates were comparable for gefitinib and erlotinib in
these two studies (8% vs. 9%, respectively).1,2
As the ISEL result was surprising, a number of comparisons
have been made.3
In ISEL 45% of patients had progressed and only 18%
responded on the most recent chemotherapy, whereas for BR21
28% progressed and 38% had responded, the more refractory
patients may have had less chance of benefiting. Erlotinib has a
greater affinity for the receptor and was used at the MTD
(150 mg) the similar dose for gefitinib would be 700 mg not the
250 mg used in ISEL. Further work investigating patient character-
istics e.g. smoking status, identification of more sensitive popula-
tions and molecular markers will be important.
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S54. PROTEIN LYSATE ARRAY ASSESSMENT OF THERAPEUTIC
TARGETS IN SARCOMA
Dennis P.M. Hughes. Children’s Cancer Hospital at M. D. Anderson
Cancer Center, TX, USA.
Small molecule inhibitors have brought new hope for cancers
with dire prognoses. These molecular medicines turn off specific
signaling intermediaries within cells, leaving others unaffected.
Their efficacy has been demonstrated clinically with medicines
such as imatinib for CML and GI stromal tumor and erlotinib for
EGFR-dependent head and neck, lung and breast cancer. More
small molecules are being developed. To rationally apply this
development to more diseases, a rapid screening tool is required
to identify expression and activity of protein targets in an individ-
ual patient’s tumor. The technical challenges for this tool are sig-
nificant: assessing dozens, if not hundreds, of potential targets
accurately using the small amount of tissue available through
core needle biopsies. We have begun applying a novel technology
– protein lysate array analysis – to address this problem in sar-
coma. Tumor lysates are arrayed on nitrocellulose matrix using
a modified DNA arrayer, creating 100+ duplicate slides using as
little as one microgram total protein. Individual slides are assayed
with monospecific antibodies and comparisons made between
phospho- and total protein levels, identifying the activation state
of dozens of potential therapeutic targets. We have used this
technique preclinically to test the downstream effects of erlotinib
in osteosarcoma and Ewing sarcoma, identifying changes in
MAPK, mTOR, AKT and JNK pathway signaling. We will use it in
a clinical trial of an anti-ERBB medicine to assess the correlation
between disease response and changes in signaling, using paired
samples of pre- and post-treatment tissue. We envision prospec-
tive testing of tumor tissue, allowing the clinician to choose those
small molecule(s) able to inhibit the specific pathway(s) active in
an individual’s tumor.
doi:10.1016/j.ejcsup.2006.04.056
S55. MOLECULAR STAGING OF NSCLC: 2006
Thomas J. Lynch Jr. Massachusetts General Hospital Cancer Center,
Boston, MA, USA.
The treatment of lung cancer has undergone a remarkable trans-
formation over the past five years. Previously histology and ana-
tomic stage were the primary determinants of treatment. While
these still have an important role, the future of treating this dis-
ease will be based on molecular staging strategies. This will allow
us to select more effective and less toxic treatments in the initial
treatment of metastatic disease. It will also permit informed
selection of patients for adjuvant treatment. Finally aggressive
molecular staging will hopefully uncover new targets that will
result in new drugs that may one day transform lung cancer into
a chronic disease with long-term survival the rule and not the
exception.
Agents that target the epidermal growth factor receptor (EGFR)
tyrosine kinase are among the most important new drugs in use
to treat non-small cell lung cancer. Both gefitinib and erlotinib are
capable of producing remarkable tumor responses as single
agents that are durable. These dramatic responses are often asso-
ciated with mutations in the EGFR tyrosine kinase domain. In
addition when used in second and third line treatment of lung
cancer erlotinib has been shown to prolong survival in this set-
ting. This clinical benefit is best predicted by increased EGFR gene
copy number as measured by FISH.
The use of EGFR-TKI provides an exceptional opportunity for
molecular staging. EGFR mutation testing is being used to select
patients for first line treatment with both gefitinib and erlotinib.
Trials in the United States, Japan and Europe are employing this
strategy and early results should be reported by the end of 2006.
The potential to identify a population of patients who might be
able to be treated with EGFR-TKI monotherapy as first line would
potentially deliver equivalent anti-tumor activity with fewer side
effects than combination chemotherapy.
Measurement of gene copy number by FISH is being used to
select patients for treatment with EGFR-TKI treatment in several
clinical scenarios. Patients who are FISH positive are being
entered onto trials of erlotinib plus chemotherapy as first line
treatment. Adjuvant studies of chemotherapy plus erlotinib given
as sequential therapy are under review. Finally there is some con-
troversy as to the relative value of EGFR protein expression as
measured by immunoperoxidase staining. Some thoughtful
investigators feel that the best way to select adjuvant and first
line metastatic patients for TKI treatment is by using a combina-
tion of FISH and immunoperoxidase staining.
While FISH and immunoperoxidase may be important modal-
ities in the molecular staging of lung cancer, mutation testing
offers a potential benefit not available with those methods.
Patients who are resistant to EGFR-TKI treatment have been found
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